The association between infectious burden and Parkinson's disease: Acase-control study

Parkinsonism and Related Disorders

Volumn 21, Issue 8, 2015, Pages 877-881

  Bu, Xian Le ^a   Wang, Xin ^a   Xiang, Yang ^a   Shen, Lin Lin ^a   Wang, Qing Hua ^a   Liu, Yu Hui ^a   Jiao, Shu Sheng ^a   Wang, Ye Ran ^a   Cao, Hong Yuan ^a   Yi, Xu ^a   Liu, Cheng Hui ^a   Deng, Bo ^a   Yao, Xiu Qing ^a   Xu, Zhi Qiang ^a   Zhou, Hua Dong ^a   Wang, Yan Jiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alpha synuclein; Case control study; Infections; Parkinson's disease; Risk factors

Indexed keywords

ALPHA SYNUCLEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; BACTERIUM ANTIBODY; VIRUS ANTIBODY;

AGED; ANTIBODY TITER; ARTICLE; BACTERIAL LOAD; BLOOD ANALYSIS; BORRELIA BURGDORFERI; CASE CONTROL STUDY; CHLAMYDOPHILA PNEUMONIAE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HELICOBACTER PYLORI; HERPES SIMPLEX VIRUS 1; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARKINSON DISEASE; PATHOGEN LOAD; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS LOAD; BLOOD; CHLAMYDIA PNEUMONIAE; GRAM NEGATIVE BACTERIUM; HERPESVIRIDAE; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR;

AGED; ALPHA-SYNUCLEIN; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; BORRELIA BURGDORFERI; CASE-CONTROL STUDIES; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; FEMALE; GRAM-NEGATIVE BACTERIA; HELICOBACTER PYLORI; HERPESVIRIDAE; HERPESVIRUS 1, HUMAN; HERPESVIRUS 4, HUMAN; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS;

EID: 84937521706     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.05.015     Document Type: Article

References (37)

1. Gerfen C.R. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 2000, 23:S64-S70.
2. Lee P.H., Lee G., Park H.J., Bang O.Y., Joo I.S., Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J.Neural Transm. 2006, 113:1435-1439.
3. El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006, 20:419-425.
4. Hu Y., Yu S.Y., Zuo L.J., Cao C.J., Wang F., Chen Z.J., et al. Parkinson disease with REM sleep behavior disorder: Features, alpha-synuclein, and inflammation. Neurology 2015, 84:888-894.
5. Stoessl A.J. Etiology of Parkinson's disease. Can. J. Neurol. Sci. 1999, 26(Suppl 2):S5-S12.
6. Liu B., Gao H.M., Hong J.S. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ. Health Persp. 2003, 111:1065-1073.
7. De Chiara G., Marcocci M.E., Sgarbanti R., Civitelli L., Ripoli C., Piacentini R., et al. Infectious agents and neurodegeneration. Mol. Neurobiol. 2012, 46:614-638.
8. Kumar A., Calne S.M., Schulzer M., Mak E., Wszolek Z., Van Netten C., et al. Clustering of Parkinson disease: shared cause or coincidence?. Arch. Neurol. 2004, 61:1057-1060.
9. Rupprecht H.J., Blankenberg S., Bickel C., Rippin G., Hafner G., Prellwitz W., et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001, 104:25-31.
10. Elkind M.S., Ramakrishnan P., Moon Y.P., Boden-Albala B., Liu K.M., Spitalnik S.L., et al. Infectious burden and risk of stroke: the northern Manhattan study. Arch. Neurol. 2010, 67:33-38.
11. Bu X.L., Yao X.Q., Jiao S.S., Zeng F., Liu Y.H., Xiang Y., et al. Astudy on the association between infectious burden and Alzheimer's disease. Eur. J. Neurol. 2014 Jun 9, 10.1111/ene.12477.
12. Ferrari C.C., Tarelli R. Parkinson's disease and systemic inflammation. Park. Dis. 2011, 2011:436813.
13. Sawada H., Oeda T., Umemura A., Tomita S., Hayashi R., Kohsaka M., et al. Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. PloS One 2014, 9:e85886.
14. Meara J., Bhowmick B.K., Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999, 28:99-102.
15. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J.Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
16. Strandberg T.E., Pitkala K.H., Linnavuori K.H., Tilvis R.S. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. Stroke 2003, 34:2126-2131.
17. Marttila R.J., Rinne U.K., Halonen P., Madden D.L., Sever J.L. Herpesviruses and parkinsonism. Herpes simplex virus types 1 and 2, and cytomegalovirus antibodies in serum and CSF. Arch. Neurol. 1981, 38:19-21.
18. Cassarino D.S., Quezado M.M., Ghatak N.R., Duray P.H. Lyme-associated parkinsonism: a neuropathologic case study and review of the literature. Arch. Pathol. Lab. Med. 2003, 127:1204-1206.
19. Pierantozzi M., Pietroiusti A., Sancesario G., Lunardi G., Fedele E., Giacomini P., et al. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients. Neurol. Sci. 2001, 22:89-91.
20. Nielsen H.H., Qiu J., Friis S., Wermuth L., Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur. J. Neurol. 2012, 19:864-869.
21. Tan A.H., Mahadeva S., Marras C., Thalha A.M., Kiew C.K., Yeat C.M., et al. Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Park. Relat. Disord. 2015, 21:221-225.
22. Salvatore M.F., Spann S.L., Mcgee D.J., Senkovich O.A., Testerman T.L. Helicobacter pylori Infection Induces Parkinson's Disease Symptoms in Aged Mice. Presentation at the American Society for Microbiology General Meeting 2011.
23. Wang W.Z., Fang X.H., Cheng X.M., Jiang D.H., Lin Z.J. Acase-control study on the environmental risk factors of Parkinson's disease in Tianjin, China. Neuroepidemiol 1993, 12:209-218.
24. Woulfe J.M., Gray M.T., Gray D.A., Munoz D.G., Middeldorp J.M. Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease. Park. Relat. Disord. 2014, 20:685-694.
25. Rees K., Stowe R., Patel S., Ives N., Breen K., Clarke C.E., et al. Helicobacter pylori eradication for Parkinson's disease. Cochrane Db Syst. Rev. 2011, CD008453.
26. Saijo K., Winner B., Carson C.T., Collier J.G., Boyer L., Rosenfeld M.G., et al. ANurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
27. Brown G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem. Soc. T 2007, 35:1119-1121.
28. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Brit. J. Pharmacol. 2007, 150:963-976.
29. Barcia C., Ros C.M., Annese V., Gomez A., Ros-Bernal F., Aguado-Llera D., et al. IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell. Death Dis. 2012, 3:e379.
30. Lema Tome C.M., Tyson T., Rey N.L., Grathwohl S., Britschgi M., Brundin P. Inflammation and alpha-synuclein's prion-like behavior in Parkinson's disease-is there a link?. Mol. Neurobiol. 2013, 47:561-574.
31. Griffin W.S., Liu L., Li Y., Mrak R.E., Barger S.W. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J.Neuroinflammation 2006, 3:5.
32. Gao H.M., Kotzbauer P.T., Uryu K., Leight S., Trojanowski J.Q., Lee V.M. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J.Neurosci. 2008, 28:7687-7698.
33. Woulfe J., Hoogendoorn H., Tarnopolsky M., Munoz D.G. Monoclonal antibodies against Epstein-Barr virus cross-react with -synuclein in human brain. Neurology 2000, 55:1398-1401.
34. Woulfe J.M., Duke R., Middeldorp J.M., Stevens S., Vervoort M., Hashimoto M., et al. Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology 2002, 58:1435-1436.
35. Gabrielli M., Bonazzi P., Scarpellini E., Bendia E., Lauritano E.C., Fasano A., et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov. Disord. 2011, 26:889-892.
36. Tan A.H., Mahadeva S., Thalha A.M., Gibson P.R., Kiew C.K., Yeat C.M., et al. Small intestinal bacterial overgrowth in Parkinson's disease. Park. Relat. Disord. 2014, 20:535-540.
37. Scheperjans F., Aho V., Pereira P.A., Koskinen K., Paulin L., Pekkonen E., et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov. Disord. 2015, 30:350-358.